Sort
4,870 grants matching “glp 1”
Novel drug combinations for improving survival from acute radiation syndrome when administered 48 hours post- irradiation
$1,000,000George Norbert Cox · Bolder Biotechnology, Inc. · R44 · FY2023 · AI
Immunotherapy of MRSA Osteomyelitis
$1,000,000M. Javad Aman · Integrated Biotherapeutics, Inc. · R44 · FY2021 · AI
A Human Fc Bifunctional Fusion Protein to Treat Severe Allergic Asthma
$1,000,000Nolan Sigal · Tunitas Therapeutics, Inc. · R44 · FY2013 · AI
Long-acting Growth Hormone for Treating HIV-Associated Adipose Redistribution Syn
$1,000,000George Norbert Cox · Bolder Biotechnology, Inc. · R44 · FY2009 · AI
New oral antibiotics focused on treating MDR Gram-negative infections
$1,000,000Charles Testa · Curza Inc · R44 · FY2025 · AI
Naloxone Nasal Spray Development
$1,000,000Daniel Paul Wermeling · Antiop, Inc. · R42 · FY2013 · DA
Hepatoselective Dihydrozuinolizone (HS-DHQ) Molecules for Treatment and Prevention of Hepatitis A Virus (HAV) Infection
$1,000,000Yanming Du · Harlingene Life Sciences Llc · R42 · FY2025 · AI
TP508: A New Drug for Mitigating Lethals Effects of Radiation Exposure
$1,000,000Laurie E Sower · Chrysalis Biotherapeutics, Inc. · R44 · FY2018 · AI
GMP production and GLP safety of bidirectionally targeted SARS-CoV-2 booster vaccine
$1,000,000Ellen Elizabeth Sparger · Tendel Therapies Inc. · R44 · FY2023 · AI
A New Class of Broad-Spectrum Antibacterial Agents to Treat Multi-Drug Resistant Pathogens
$1,000,000Paul Sebahar · Curza Inc · R44 · FY2024 · AI
Pre-clinical Development of a Broad Spectrum Antiviral Compound to Treat Human Pa
$1,000,000Christopher Fisher · Nanovir, Llc. · R42 · FY2011 · AI
Advancing a broad-spectrum anti-influenza A virus RNA packaging inhibitor to an IND
$1,000,000Jeffrey S Glenn · Stanford University · R01 · FY2017 · AI
A Human Fc Bifunctional Fusion Protein to Treat Severe Allergic Asthma
$1,000,000Nolan Sigal · Tunitas Therapeutics, Inc. · R44 · FY2015 · AI
Third line treatment of drug resistant FLT3-positive acute myeloid leukemia with a novel FLT3 kinase inhibitor
$1,000,000Frederick Wayne Holtsberg · Kinarx, Llc · R44 · FY2020 · CA
Novel HBV Therapeutic with Potential for Treatment of Drug-Resistant Infection
$1,000,000Andrea Cuconati · Pharmabridge, Inc. · R44 · FY2011 · AI
Development of a Novel PolC Inhibitor as a Gram-Positive Antibiotic
$1,000,000Thale Cross Jarvis · Crestone, Inc. · R44 · FY2014 · AI
New oral antibiotics focused on treating MDR Gram-negative infections
$1,000,000Charles Testa · Curza Inc · R44 · FY2024 · AI
Commercialization of an MRI contrast agent for differential diagnosis of prostate cancer
$1,000,000Songqi Gao · Molecular Theranostics, Llc · R44 · FY2023 · CA
Development of a Novel PolC Inhibitor as a Gram-Positive Antibiotic
$1,000,000Thale Cross Jarvis · Crestone, Inc. · R44 · FY2012 · AI
Pre-clinical Development of a Broad Spectrum Antiviral Compound to Treat Human Pa
$1,000,000Christopher Fisher · Nanovir, Llc. · R42 · FY2010 · AI
A next-generation meningococcal serogroup B vaccine with improved effectiveness for all age groups
$1,000,000Gregory Robert Moe · Omvax, Inc. · R44 · FY2022 · AI
Pre-clinical Development of a Broad Spectrum Antiviral Compound to Treat Human Pa
$1,000,000Christopher Fisher · Nanovir, Llc. · R42 · FY2012 · AI
TP508: A New Drug for Mitigating Lethals Effects of Radiation Exposure
$1,000,000Laurie E Sower · Chrysalis Biotherapeutics, Inc. · R44 · FY2016 · AI
TP508: A New Drug for Mitigating Lethal Effects of Radiatin Exposure
$1,000,000Barbara Maria Olszewska-Pazdrak · Chrysalis Biotherapeutics, Inc. · R44 · FY2012 · AI
A Novel Immunologically Enhanced Probiotic for Treating Rheumatoid Arthritis
$1,000,000Gary Fanger · Rise Therapeutics, Llc · R44 · FY2022 · AI